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Chronic respiratory infection, mainly caused by Pseudomonas aeruginosa and 
Burkholderia cepacia complex, is the major cause of complications and eventually of 
death in patients with cystic fibrosis. These problems are exacerbated by drug resistance 
mechanisms induced in the infectious microorganisms, and by persistence of the 
tnicroorganistns by sequestration in viscous mucus or biofilms. The sequestration 
prevents effective antibiotic access to the bacteria. Such probletns have led to the search 
for alternative treatments and therapies, but none of these alternative techniques have 
yet been tested rigorously or successfully in clinical patients. In this project, we used a 
standard strain of P. aeruginosa (NCTC 1 0662) and a B. cenocepacia isolate from 
cystic fibrosis sputmn to appraise tobramycin/amikacin efficacy in combination with 
clinically relevant concentrations of the adjunctive agents atni1oride, benzami1 
hydrochloride, phenamil, salbutamol, verapatnil , and atn1odipine. Altered conditions in 
the cystic fibrosis lung were sin1ulated by using different concentrations of sodiun1 
chloride, potassiUin chloride, sodium gluconate, D-tnannitol , and N-Methyl-D-
glucan1ine. Benzamil hydrochloride was the 1nost potent additive cmnpound against the 
organistns tested; enhancing the antibacterial effect of tobramycin. A sub-inhibitory 
concentration of amlodipine was only marginally useful, even though its minimum 
inhibitory concentration (MIC) against both microbes was the lowest of all the non-
antibiotic cmnpounds tested . Conversely, salbutamol, verapamil, and an1lodipine were 
antagonistic in some combinations with tobramycin. Amikacin was generally more 
potent than tobratnycin. Sodiwn and potassium chlorides and sodium gluconate 
increased the tobramycin MIC up to 8-fold at salt concentrations from 50-400 mM. 
This antagonistic effect of cations appeared to be partially reversed by adding amiloride, 
verapamil, or salbutamol. This study needs to be extended by further assays with more 
clinical isolates, but it has shown that non-antibiotic adjunctive agents can be used with 
antibiotics to produce effective results in vitro; and potentially in vivo as an alten1ative 
regitne for the treatrnent of chronic airway infections in cystic fibrosis patients. 
